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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYCancer stem cells (CSC) are responsible for cancer chemoresistance and metastasis formation. Here we report that D133p53b, a TP53
splice variant, enhanced cancer cell stemness in MCF-7 breast cancer cells, while its depletion reduced it. D133p53b stimulated the
expression of the key pluripotency factors SOX2, OCT3/4, and NANOG. Similarly, in highly metastatic breast cancer cells, aggressiveness
was coupled with enhanced CSC potential and D133p53b expression. Like in MCF-7 cells, SOX2, OCT3/4, and NANOG expression were
positively regulated by D133p53b in these cells. Finally, treatment of MCF-7 cells with etoposide, a cytotoxic anti-cancer drug, increased
CSC formation and SOX2, OCT3/4, and NANOG expression via D133p53, thus potentially increasing the risk of cancer recurrence. Our
findings show that D133p53b supports CSC potential. Moreover, they indicate that the TP53 gene, which is considered a major tumor
suppressor gene, also acts as an oncogene via the D133p53b isoform.INTRODUCTION
The p53 functions are ubiquitously altered in cancer
cells by mutations/perturbation of its signaling path-
ways, and loss of p53 activity is a prerequisite for cancer
development. Mutant p53 is thought to play a pivotal
role in promoting invasion, favoring cancer cell exit
from the primary tumor site and dissemination, ulti-
mately leading to metastasis formation (Gadea et al.,
2007; Muller et al., 2009; Roger et al., 2010; Vinot
et al., 2008).
Recent reports have documented a p53 role in stem
cell homeostasis and pluripotency. Wild-type (WT) p53
counteracts somatic cell reprogramming (Hong et al.,
2009; Kawamura et al., 2009; Liu et al., 2009; Utikal
et al., 2009), whereas mutant p53 stimulates induced
pluripotent stem (iPS) cell formation (Sarig et al.,
2010). Depletion of p53 significantly increases cell re-
programming efficacy and facilitates iPS cell generation
(Kawamura et al., 2009). Consequently, p53 might be
considered as the guardian of the genome and also of
reprogramming.
All these functions are associated with full-length p53
(i.e., the TAp53a isoform). However, the TP53 gene en-
codes at least 12 different physiological isoforms (TAp53
[a, b, and g], D40p53 [a, b, and g], D133p53 [a, b, and g],
and D160p53 [a, b, and g]) (Bourdon, 2007) via severalStemmechanisms: alternative promoters (the TA and D133 iso-
forms), alternative intron splicing (intron 2: D40 isoforms
and intron 9: a, b, and g isoforms), and alternative transla-
tional initiation sites (D40 andD160 isoforms). The TAp53a
isoform is the best described and classically mentioned in
the literature as p53. Basically, p53 isoforms can be divided
into two groups as follows: (1) long isoforms that contain
the transactivation domain (TA and D40), and (2) short iso-
forms without the transactivation domain (D133 and
D160). Furthermore, the b and g isoforms do not contain
the canonical C-terminal oligomerization domain, but an
additional domain with unknown function(s) (Khoury
and Bourdon, 2011).
The p53 isoforms modify p53 transcriptional activity
in many processes, such as cell-cycle progression, pro-
grammed cell death, replicative senescence, cell differenti-
ation, viral replication, and angiogenesis (Aoubala et al.,
2011; Bernard et al., 2013; Bourdon et al., 2005; Marcel
et al., 2012; Terrier et al., 2011, 2012). Importantly, p53
isoforms are specifically deregulated in human tumors
(Machado-Silva et al., 2010). However, the functions of
p53 isoforms in cancer stem cell (CSC) homeostasis have
never been explored.
Here, we show that the D133p53b isoform is specifically
involved in promoting cancer cell stemness. Overexpres-
sion of D133p53b in human breast cancer cell lines stimu-
lated mammosphere formation and the expression of keyCell Reports j Vol. 4 j 531–540 j April 14, 2015 j ª2015 The Authors 531
AB C
D E
F G
Figure 1. Selective Depletion of p53 Iso-
forms Affects the Sphere-Forming Ability
of MCF-7 Cells
(A) Schematic representation of p53 iso-
forms with the targets of the different
shRNAs (Sh) used in this study. The calcu-
lated molecular weights of the different
isoforms are indicated.
(B) Mammosphere quantification in MCF-7
cells after transduction of Sh1, Sh2, Sh3,
Sh4, and Sh5 (n = 3 independent experi-
ments).
(C–E) Western blot analysis of p53 isoform
depletion in the corresponding cells.
(F and G) The qRT-PCR quantification of the
expression levels of C-MYC, SOX2, OCT3/4,
and NANOG (F) as well as of D133p53
and p53 b isoforms (G) after transduction
with Sh1 and Sh2 (n = 4 independent
experiments).pluripotency and stemness regulators (SOX2, OCT3/4,
and NANOG and CD24/CD44), but not C-MYC. Further-
more, using MDA-MB-231-based cell lines, we show that
increased expression of D133p53 isoforms correlates with
the increasedmetastatic potential and withmammosphere
formation. Finally, incubation ofMCF-7 andMDA-MB-231
cells with the anti-cancer drug etoposide also promoted cell
stemness in a D133p53-dependent manner. Our results
demonstrate that short p53 isoforms positively regulate
CSC potential regardless of any p53 mutation. Conse-
quently, WT TP53, which is considered a tumor suppressor
gene, also can act as an oncogene through D133p53b
expression.532 Stem Cell Reports j Vol. 4 j 531–540 j April 14, 2015 j ª2015 The AuthoRESULTS
Changes in the Expression of p53 Isoforms Affect
Mammosphere Formation
To study the role of the different p53 isoforms in CSC
potential, we designed small hairpin RNAs (shRNAs)
(Sh) that selectively silence specific groups of isoforms
(Figure 1A; Table S1). Briefly, Sh1 knocks down all p53
isoforms, while Sh2 targets the long TAp53 (trans-acti-
vating) and D40p53 isoforms. Sh3 and Sh4 target the
50 UTR of the D133 isoforms (a, b, and g), and Sh5 and
Sh6 respectively target the 30 end of the b and a
isoforms.rs
First, we tested the ability of MCF-7 cells to form mam-
mospheres, an assay widely used to assess CSC potential
in vitro. Silencing of all p53 isoforms (with Sh1) resulted
in a significant reduction of mammosphere formation
compared to control cells, while knockdown of the TAp53
and D40p53 isoforms (Sh2) had no effect (Figures 1B and
1C). In parallel wemeasured themRNA (Figure 1F) and pro-
tein (Figure S1A) expression of C-MYC, SOX 2, OCT 3/4,
and NANOG, which are key regulators of cell pluripotency.
TAp53 and D40p53 (Sh2) silencing resulted in increased
expression of OCT 3/4, NANOG, and SOX 2, but not of
C-MYC,while depletion of all p53 isoforms (Sh1) hadno ef-
fect. Moreover, depletion of TAp53 and D40p53 (Sh2)
increased the expression of the D133 isoforms (Figure 1G).
These results suggest that the CSC potential in MCF-7
cells is not only regulated by TAp53a, which previously
was identified as a suppressor of stemness. To investigate
this hypothesis, we depleted all D133 isoforms using two
different shRNAs (Sh3 and 4). Both shRNAs, used either
alone or in combination, significantly reduced mammo-
sphere formation in MCF-7 cells, suggesting that these iso-
forms are key regulators of the CSC potential (Figures 1B
and 1D). Accordingly, OCT3/4, NANOG, and SOX2 were
significantly downregulated in D133-isoform-silenced cells
(Figure S1A). Again C-MYC expressionwas not affected.We
then evaluated the effect of b and a isoform silencing.
Mammosphere formationwas significantly reduced in cells
in which b isoforms where knocked down (Sh5; Figure 1B).
Silencing of all a isoforms (Sh6) did not affect mammo-
sphere formation (Sh6; Figures S1B and S1C). Altogether
these findings suggest that D133p53 (a, b, and g) isoforms
are involved in regulating CSC potential in MCF-7 cells.
The D133p53b Isoform Promotes CSC Potential
in MCF-7 Cells
Indeed, mammosphere formation was significantly in-
creased in MCF-7 cells that expressed only the D133p53b
and D133p53g isoforms following concomitant transduc-
tion with Sh2 and Sh6 (Figures 2A and 2B). To confirm
that sphere increase was indicative of the CSC phenotype,
we analyzed the proportion of CD44+/CD24 cells, because
this subpopulation of cancer cells are considered to have
CSC properties. Similar to mammosphere formation va-
riations, the proportion of CD44+/CD24 cells was not
affected by TAp53 and D40p53 isoform silencing with
Sh2, whereas it was increased by co-transduction of Sh2
and Sh6 (Figure 2C).
To determine the specific contribution of the D133p53
(b and g) isoforms in promotingmammosphere formation,
we overexpressed them separately. In agreement with the
previous results, D133p53b overexpression significantly
promotedmammosphere formation, while g isoform over-
expression had a milder effect (Figures 2D and S2). More-Stemover, D133p53b overexpression resulted in a significant
increase of SOX2, NANOG, and OCT3/4 expression, but
not of C-MYC (Figure 2E). In addition, mammosphere
formation by D133p53b-expressing cells was higher after
harvesting and re-plating of primary mammospheres,
which is considered the gold standard experiment to chal-
lenge the CSC phenotype in vitro (Figure 2F).
Finally, to confirm the role of the D133p53b isoform in
promoting CSC potential in MCF-7 cells, we overexpressed
a Sh1-resistant D133p53b isoform in MCF-7 cells in which
all p53 isoforms had been knocked down with Sh1. As
expected, expression of Sh1-resistant D133p53b rescued
mammosphere formation (Figure 2G). These results indi-
cate that the D133p53b isoform positively regulates CSC
potential in MCF-7 breast cancer cells.
High D133p53 Levels Correlate with Increased
Metastatic Capacity and Mammosphere Formation
Increasing evidence suggests that the CSC phenotype and
metastasis development are closely linked. We therefore
asked whether the metastatic capacity of breast cancer cells
was coupled to their CSC potential and D133p53 isoform
expression. To this end, we used MDA-MB-231 D3H2LN
cells, which can generate, at low frequency, lungmetastasis
when transplanted in immunodeficient mice, to derive
the highly cancer-prone and very metastatic C3LND cell
line (Figures S3A and S3B). When this line was used for
orthotopic transplantation experiments in nude mice,
metastasis detection time was reduced from 82 days (with
parental D3H2LN cells) to 20 days, and lung metastases
were detected in all transplanted animals (Figure S3C).
Although primary tumor growth was comparable in both
cell lines (Figure S3D), metastasis development was signifi-
cantly accelerated in the C3LND cells, as indicated by
bioluminescence quantification (Figure S3E).
Evaluation of mammosphere formation in D3H2LN and
C3LND cells showed that C3LND cells formed two times
more mammospheres (Figure 3A). Similarly, D133p53 iso-
form expression was 3-fold higher and OCT3/4, NANOG,
and SOX2 levels were 2- to 3-fold higher in C3LND (Figures
3B and 3C). C-MYC expression was comparable in the two
cells lines. We then asked whether pluripotency factor
expression could be affected by changes in D133p53
expression. Overexpression of D133p53b in D3H2LN cells
resulted in a significant increase of OCT3/4, NANOG, and
SOX2 expression, whereas C-MYC level was not affected,
consistent with data in MCF-7 cells (Figures 3D and 3E).
Similar results were obtained in C3LND cells (Figure S3F).
In complete agreement with observations in MCF-7,
D133p53b overexpression inD3H2LNcells resulted in a sig-
nificant increase of mammosphere formation (Figure 3F).
Conversely, knockdown of the D133p53 isoforms with
Sh3 in C3LND cells led to a significant reduction of sphereCell Reports j Vol. 4 j 531–540 j April 14, 2015 j ª2015 The Authors 533
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Figure 2. The Isoform D133p53b Pro-
motes CSC Potential in MCF-7 Cells
(A and B) Mammosphere quantification in
MCF-7 cells after silencing with Sh2 (shRNAs
against the TA and D40 isoforms) or with
Sh2 and Sh6 (against the 30 end of the a
isoforms) (A) and western blot analysis to
confirm p53 depletion in the corresponding
cell cultures (B) (n = 3 independent exper-
iments).
(C) Representative fluorescence-activated
cell sorting (FACS) dot blots for the double
labeling of CD24 and CD44 in MCF-7 trans-
duced with Sh Luc (Control), Sh2, or Sh2 + 6.
(D and E) Mammosphere quantification
in MCF-7 cells after D133p53b or g over-
expression (D) and qRT-PCR analysis of
C-MYC, SOX2, OCT3/4, and NANOG (E)
expression in the corresponding cells (n = 4
independent experiments).
(F) Mammosphere quantification in MCF-7
cells that overexpress D133p53b after har-
vesting and re-plating of the primary
mammospheres (n = 4 independent experi-
ments).
(G) Mammosphere quantification in MCF-7
cells in which all p53 isoforms have been
silenced with Sh1 and after expression in
the same cells of Sh1-resistant D133p53b
(n = 3 independent experiments).formation; a marked decrease of OCT3/4, NANOG, and
SOX2 expression; and a small increase of C-MYC level
(Figures 3G–3I), whereas D133p53b transduction increased
them (Figure S3F). In agreement, Sh3 transduction de-
creased the proportion of CD44+/CD24 cells (Figure 3J).
Finally, after intracardiac injection in athymic mice, Sh3-
transduced C3LND cells were less prone to metastasize
to distant sites compared to control cells (Figures 3K, 3L,
S3G, and S3L).
In summary, the more metastatic C3LND cell line is
characterized by higher CSC potential, as indicated by534 Stem Cell Reports j Vol. 4 j 531–540 j April 14, 2015 j ª2015 The Authomammosphere formation and increased D133p53 as well
asOCT3/4,NANOG, and SOX2 (but not C-MYC) expression
compared to the parental D3H2LN cell line. D133p53
overexpression increases the pluripotency potential of
D3H2LN cells, while its knockdown produces the opposite
effect and a marked reduction of their metastatic potential
when grafted in mice. Altogether these data suggest that
the D133p53b isoform specifically regulates CSC activity
and metastasis formation through modulation of the
expression of key cell pluripotency and reprogramming
factors (i.e., OCT3/4, NANOG, and SOX2).rs
Chemotherapy Treatment of Breast Cancer Cell Lines
Upregulates the Expression of D133p53 Isoforms and
Activates Key Reprogramming Genes
Topoisomerase II inhibitors (etoposide-VP16 and doxoru-
bicin) are frequently used as adjuvant chemotherapy treat-
ment for several cancer types alone or in combinationwith
other drugs (cisplatin most frequently). Topoisomerase II
inhibitors induce double-strand DNA breaks, a genotoxic
stress that strongly activates p53 signaling. Upregulation
of TAp53 should be beneficial due to its ability to induce
cell-cycle arrest, apoptosis, and to negatively regulate cell
reprogramming. We thus assessed whether etoposide
could affect D133p53 expression and CSC potential in
breast cancer cell lines. Increasing concentrations of eto-
poside resulted in TAp53a stabilization in MCF-7. As ex-
pected, p21 expression (positively regulated by p53) was
increased, whereas C-MYC expression (negatively regu-
lated by p53) was reduced (Figure 4A), as also confirmed
by qRT-PCR quantification (Figure 4B). Moreover, qRT-
PCR and western blot analysis showed that, upon etopo-
side treatment, D133p53 isoforms (Figures 4C and 4D) as
well as OCT3/4, NANOG, and SOX2 (Figure 4E) were
strongly upregulated in a dose-dependent manner. This
last result is particularly intriguing because TAp53a, which
is considered as a negative regulator of pluripotency/re-
programming genes, is stabilized and transcriptionally
active.
To determine whether OCT3/4, NANOG, and SOX2 upre-
gulation in this condition required D133p53 expression,
we transduced MCF-7 cells with Sh3 to specifically knock
them down. OCT3/4, NANOG, and SOX2 expression were
reduced in both etoposide-treated and untreated cells
following D133p53 silencing (Figure 4F), confirming the
specific role ofD133p53 isoforms in the regulation of genes
involved in cell pluripotency/reprogramming.
Finally, we evaluated the effect of etoposide treatment on
mammosphere formation in Sh2-transduced MCF-7 cells.
Etoposide treatment in control cells (active TAp53) signifi-
cantly reduced mammosphere formation, whereas it did
not have any significant effect in Sh2-transduced cells (Fig-
ure 4G). Moreover, D133p53 level was correlated with the
expression of reprogramming genes (Figures 4H and 4I).
These data indicate that TAp53 and D133p53b have an
antagonistic action in sphere formation.
We then evaluated the effects of etoposide treatment in
MDA-MB-231 D3H2LN cells that harbor the p53 R280K
mutation and correspond to a triple-negative breast cancer
type. This mutation is present in TAp53 and also in
D133p53 isoforms. Incubation with increasing concentra-
tions of etoposide did not affect TAp53 expression, and
p21 expression was only weakly increased (Figure S4A).
This effect of mutant p53 protein on p21 expression
already has been described in the literature (Bieging et al.,Stem2014). Interestingly, C-MYC expression was significantly
downregulated (Figures S4A and S4B). The expression of
D133p53 isoforms was upregulated (Figures S4A and
S4C), but not in a dose-dependent manner, as observed
in MCF-7 cells. Similarly, the expression of NANOG,
SOX2, and OCT3/4 (Figure S4D) also was upregulated
following incubation with etoposide, like for D133p53
isoforms.
These data suggest that, in human breast cancer cells, the
topoisomerase II inhibitor etoposide increases D133p53
expression, resulting in the activation of the reprogram-
ming genes NANOG, SOX2, and OCT3/4.DISCUSSION
In this work, by modulating p53 isoform expression in
breast cancer cell lines, we show that D133p53 isoforms
have a role in regulating their stemness potential. Surpris-
ingly, depletion of all p53 isoforms in MCF-7 cells signifi-
cantly reduced mammosphere formation (a hallmark of
CSC potential), although previous reports indicate that
TAp53a hinders cell reprogramming. Conversely, selective
depletion of TAp53 and D40p53 isoforms with the Sh2
shRNA did not affect mammosphere formation, suggest-
ing that D133p53 isoforms are responsible for this activity.
We then confirmed this hypothesis by showing that mam-
mosphere formation was strongly reduced upon knock-
down of these small isoforms (Figure 1). Similarly, deple-
tion of the b isoforms had a deleterious effect on the
capacity of MCF-7 cell to form mammospheres, while
depletion of the a isoforms did not have any effect. More-
over, all changes in p53 isoform expression, particularly
D133p53, were associated with variations in the expres-
sion of SOX2, OCT3/4, and NANOG, key cell pluripo-
tency/reprogramming genes, but not of C-MYC (Figures 1
and 2). Furthermore, the finding that D133p53b isoform
specifically promoted mammosphere formation and
increased the proportion of CD44+/CD24 cells indicates
that this isoform positively regulates CSC potential in
MCF-7 breast cancer cells. Indeed, our data show that
D133p53b expression positively correlates with SOX2,
OCT3/4, and NANOG expression, genes responsible for
cell pluripotency induction and maintenance (Figure 2).
Finally, using a breast cell model of tumor aggressiveness,
we show that higher metastatic potential and chemore-
sistance are coupled with increased expression of the
D133p53 isoforms, CSC stemness, and increased expres-
sion of key pluripotency/reprogramming genes (Figures 3
and 4).
Importantly, our results show that TAp53 (a, b, and g)
silencing does not affect CSC formation, whereas
D133p53 (a, b, and g) silencing does, indicating that theCell Reports j Vol. 4 j 531–540 j April 14, 2015 j ª2015 The Authors 535
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CSC potential is mainly regulated by D133p53 activity
rather than by TAp53.These findings challenge the promi-
nent role of full-length p53 (TAp53a) in CSC regulation
and clearly indicate that most of the p53-mediated regula-
tion of the CSC potential is via the short p53 isoforms.
While the role of TAp53 (full-length p53) in CSC forma-
tion has been largely documented, the role of other p53
isoforms is still poorly described. The isoform D40p53, a
highly expressed isoform in embryonic stem cells, has
been proposed to control pluripotency by maintaining
TAp53 in an inactive form (Ungewitter and Scrable,
2010). Thus, the p53 stemness response could be deter-
mined by the composition of the complexes formed by
different p53 isoforms with synergistic or antagonistic ac-
tivity. Our data indicate thatD133p53b effects aremediated
through regulation of SOX2, OCT3/4, and NANOG expres-
sion. As TAp53 is a negative regulator of these genes, it is
tempting to suggest a dominant-negative effect of the
D133p53b isoform as a mechanism of action. However,
D133p53b did not affect the expression of C-MYC, another
TAp53-regulated gene. Thus, we cannot exclude the possi-
bility of gain-of-function properties for the small isoforms
relative to the long ones, as suggested by etoposide treat-
ment experiments. A similar mechanism has been pro-
posed already for the mutated p53 variants that facilitate
somatic cell reprogramming and increase the malignant
potential of reprogrammed cells (Sarig et al., 2010). Gain-
of-function properties of p53 isoforms also are involved
in the regulation of some aspects of cell-cycle progression
(Olivares-Illana and Fa˚hraeus, 2010). In any case, these
two mechanisms (dominant-negative and gain-of-func-
tion effects) are not mutually exclusive and further studies
are needed to evaluate their contribution.Figure 3. Evaluation of the CSC Features of the MDA-MB-231 D3H
(A) Mammosphere quantification in the modestly metastatic, parental
lines (n = 3 independent experiments).
(B) The qRT-PCR analysis of D133p53 isoform expression in MDA-MB-
(C) The qRT-PCR quantification of C-MYC, OCT3/4, NANOG, and SOX2 exp
experiments).
(D) Western blot analysis of D133p53b-Flag transduced in MDA-MB-2
(E) The qRT-PCR analysis of C-MYC, OCT3/4, NANOG, and SOX2 expres
(n = 4 independent experiments).
(F) Mammosphere quantification in MDA-MB-231 D3H2LN cells that o
(G) Mammosphere quantification in MDA-MB-231 C3LND transduced w
(H) The qRT-PCR analysis of D133p53 isoform expression in MDA-MB-
(I) The qRT-PCR quantification of C-MYC, OCT3/4, NANOG, and SOX2 e
independent experiments).
(J) Representative FACS dot plots for the double labeling of CD44 and C
(n = 3 independent experiments).
(K) Bioluminescence ventral images of mice injected with MDA-MB-23
show relative changes at metastatic sites.
(L) Quantification of distant metastasis in brain and femur using biolu
represent mean ± SEM of biological replicates.
StemIn summary, our study shows that D133p53b plays a crit-
ical role in supporting the CSC potential of breast cancer
cells. Mutations of TP53 are considered the main mecha-
nism for inhibiting its tumor suppressor activity. Here, we
demonstrate that p53 mutations are not necessary to block
p53 tumor suppressor activity, because expression of spe-
cific p53 isoforms, particularly D133p53b, is sufficient to
increase CSC activity. Our study challenges the paradigm
that TP53 always acts as a tumor suppressor by showing
that D133p53b antagonizes TAp53a to promote CSC
potential.EXPERIMENTAL PROCEDURES
Detailed Experimental Procedures are available in the Supple-
mental Information posted online with this paper.
MDA-MB-231 C3LND Cell Line Establishment
The C3LND cell line was derived from distant metastases of
the MDA-MB-231-luc-D3H2LN cell line after two in vivo pas-
sages in nude mice. Briefly, 1 3 106 cells per animal were resus-
pended in sterile PBS for intracardiac injection (first cycle of
enrichment) or in 50% Matrigel (BD Biosciences) for injection
in the lower left mammary fat pad (second cycle of enrichment)
of athymic nude mice (Hsd:Athymic Nude-Foxn1, Harlan). Tu-
mor progression and time to metastasis were followed weekly
by whole-body bioluminescence imaging. Invaded organs
were then resected and tumor cells isolated and propagated
in vitro.
Statistical Analysis
All data are presented as the arithmetic mean ± SEM. Statistical an-
alyses were performed using the non-parametric Mann-Whitney t
test with the Prism software (GraphPad).2LN and C3LND Cell Lines
MDA-MB-231 D3H2LN and the derived, highly metastatic C3LND cell
231 D3H2LN and C3LND cells (n = 4 independent experiments).
ression in MDA-MB-231 D3H2LN and C3LND cells (n = 4 independent
31 D3H2LN cells (Flag antibody).
sion in MDA-MB-231 D3H2LN cells after D133p53b overexpression
verexpress D133p53b (n = 3 independent experiments).
ith Sh3 (n = 3 independent experiments).
231 C3LND transduced with Sh3 (n = 3 independent experiments).
xpression in MDA-MB-231 C3LND cells transduced with Sh3 (n = 4
D24 in MDA-MB-231 C3LND transduced with Sh Luc (Control) or Sh3
1 C3LND cells transduced with Sh3 or control. Pseudocolor scale bars
minescence imaging (n = 7/5) 25 days after the implantation. Bars
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In Vivo Experiments
All in vivo experiments were performed in compliance with the
French regulations and ethical guidelines for experimental animal
studies in an accredited establishment (AgreementNo.C34-172-27).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2015.
02.001.
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